Yu Si, He Xiao-Shun, Ma Yi, Hu An-Bin, Wu Lin-Wei, Zhu Xiao-Feng
Department of Gastrointestinal Surgery, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2009 Nov;29(11):2276-8.
To investigate the efficacy of conversion from calcineurin-inhibitor (CNI) to rapamycin in liver recipients with CNI-associated renal insufficiency.
This retrospective study examined the liver transplant recipients who had switched from CNI to rapamycin between January 2004 and June 2008 in the first affiliated hospital of Sun Yat-sen University. The data of renal function before and after the conversion were analyzed by Wilcoxon sum rank test, and rapamycin-related adverse effects were also observed.
Compared with that before conversion, the renal funtion 4 months after the conversion improved significantly (P<0.05). The blood lipid level 3 months after the conversion increased significantly (P<0.05) but were well controlled.
Rapamycin can be used safely as a good alternative in liver transplant recipients with CNI-related renal insufficiency.
探讨在接受钙调神经磷酸酶抑制剂（CNI）治疗且出现CNI相关肾功能不全的肝移植受者中，转换为雷帕霉素治疗的疗效。
这项回顾性研究考察了2004年1月至2008年6月间在中山大学附属第一医院从CNI转换为雷帕霉素治疗的肝移植受者。采用Wilcoxon秩和检验分析转换前后的肾功能数据，并观察与雷帕霉素相关的不良反应。
与转换前相比，转换后4个月时肾功能显著改善（P<0.05）。转换后3个月时血脂水平显著升高（P<0.05），但得到了良好控制。
对于出现CNI相关肾功能不全的肝移植受者，雷帕霉素可作为一种安全的良好替代药物使用。
